about
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.Severity of lipodystrophy is associated with decreased health-related quality of life.Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: the IMMUNEF clinical trialFocal bone lesions in HIV-positive patient treated with tenofovirUnmasking tuberculosis in the era of antiretroviral treatment.Brachial and central blood pressure in HIV-infected subjects.Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients.Ultrasonographic backscatter of the carotid artery wall in patients with HIV infection: a pilot study.Detectable HIV viral load is associated with metabolic syndrome.Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: relapse or late IRIS?Tularaemia outbreak in Bulgaria.Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study.Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: a cross-sectional study.Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and correlations with predictors of cardiovascular disease.Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: worth the risk?Prevalence of and risk factors for pubic lipoma development in HIV-infected persons.Nonalcoholic Fatty Liver Disease in HIV-Infected Persons: Epidemiology and the Role of Nucleoside Reverse Transcriptase InhibitorsMetabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular remodeling of the brachial artery in a population of HIV-infected patientsThe Role of the Framingham Risk Score to Predict the Presence of Subclinical Coronary Atherosclerosis in Patients with HIV InfectionLong-Term Psychometric Outcomes of Facial Lipoatrophy Therapy: Forty-Eight–Week Observational, Nonrandomized StudyMultidisciplinary Approach to the Treatment of Metabolic and Morphologic Alterations of HIV-Related LipodystrophySimilar Success Rates but Lower Incidence of Telaprevir-Related Rash in HIV/HCV Coinfected as Compared to HCV-Monoinfected Patients Treated With Triple Anti-HCV TherapyInvasive pulmonary and cerebral aspergillosis in a patient with Weil's diseaseNonalcoholic fatty liver disease and steatohepatitis in people living with HIV
P50
Q33817410-A76AA871-6DBB-48D2-9F23-77C28FE82DFDQ34087789-1193F8CA-39EF-44A6-ADF3-C2C13BF50ABCQ35074381-4977ED26-BFC7-4ECD-8C02-944CEEAC0FFEQ35112499-EC651E83-077A-442D-90BC-33A1E1E95E86Q37946719-E387A968-4452-42C0-988C-F3C8C95E7BABQ41294691-6D248341-B106-4F3C-8201-39F839211372Q42203659-485F23A2-7716-483C-A5FA-AAAB84035C51Q42960959-52ECBDD0-5AC4-4BF6-A70C-E0EB4D0CA40CQ43271725-6F8D5E33-716C-443C-9A1E-B6A7D0ADD732Q43830205-9F3A4EDE-BE4B-48CE-8A89-565F8A03DE66Q43928994-3F624BEB-9A42-49FC-87A2-90E99FE70EBCQ43960663-59E86F7F-1DF8-4495-877C-02FCB514195EQ45397600-E81F8DEC-D0BC-4409-A8CD-26C9AF832508Q46173738-D78796B7-0229-4E6B-B5C7-216BD1296AB2Q46557460-9D0F187C-21F2-4C28-B755-F7D8EE3A44F9Q48585925-8B8D1596-7FA4-43AE-99D2-995CE7740E6DQ51755617-F53813B7-F5C9-423D-AB1B-E17C1FBE185FQ58798016-99FA2C00-B1E6-4212-9269-3CF12CB228BBQ58798047-F2D14C1E-09A1-46DE-8563-3E2050E9E467Q58798055-7756846B-F35F-44E9-8F59-DE30502BD018Q58798102-3DF762F8-7271-452E-A818-B1CFE0B004E6Q58798126-09F9F79B-A357-4AA1-AB03-D2D9AF82D55BQ60621766-8F3B080E-2E23-4150-B96A-14138D0F29C9Q80953375-61794287-83E4-4D45-8AE1-1EE2D34085F5Q91968566-42D43AAD-D03E-4B99-A6D6-B17387BCF5D4
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicola Squillace
@ast
Nicola Squillace
@en
Nicola Squillace
@es
Nicola Squillace
@sl
type
label
Nicola Squillace
@ast
Nicola Squillace
@en
Nicola Squillace
@es
Nicola Squillace
@sl
prefLabel
Nicola Squillace
@ast
Nicola Squillace
@en
Nicola Squillace
@es
Nicola Squillace
@sl
P106
P1153
8369052600
P21
P31
P496
0000-0002-7608-6045